Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2014

View Archived Issues

Repurposing dopamine receptor antagonists antipsychotic for the treatment of brain cancer

TG-1042 shows clinical benefit in phase II study in cutaneous B-cell lymphoma

Guerbet and Sirtex Medical to collaborate on trials in liver cancer

Merck & Co. designs improved pan-genotypic HCV NS3/4A protease inhibitors

Scientists at RespiVert and Topivert Pharma synthesize novel protein kinase inhibitors

Cancer Research UK begins vaccine trial against cancer caused by Epstein-Barr virus

Courtagen Life Sciences to provide genetic testing in RP-103 study

Effective and safe silencing of CTGF with RXI-109 expected to inhibit skin scarring

Daiichi Sankyo outlines plans for TaNeDS program in 2014

NICE final guidance recommends MabThera for ANCA-associated vasculitis

Dimerix Bioscience raises funds to advance DMX-200

First patient enrolled in phase IIa trial of ORMD-0801 in type 1 diabetes

Alimera Sciences resubmits Iluvien NDA to FDA

Enrollment begins in phase III study of ZS-9 in patients with hyperkalemia

Xenon Pharmaceuticals and Genentech establish new pain genetics collaboration

First patient dosed in Norgine and Innovacell's phase IIb trial of ICEF-15

Pfizer achieves primary endpoint in phase IIIb study of Genotropin

Gemigliptin/metformin fixed-dose combination shows promise in healthy volunteers

Adipophilin as a potential new marker for Burkitt's lymphoma

Mast Therapeutics begins phase II study of MST-188 in acute lower limb ischemia

Genmab achieves second milestone in daratumumab collaboration with Janssen

Bristol-Myers Squibb patents new JAK inhibitors

Researchers at Plexxikon design novel agents for cancer

AbbVie discloses new NO production inhibitors

Transgene and partners outline development plan for Pexa-Vec

EMA validates ledipasvir/sofosbuvir MAA and grants accelerated assessment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...